Arcutis Biotherapeutics ARQT 深 沪
等待开盘 07-01 09:30:00 美东时间
26.22
-0.540
-2.02%
华盛通- 最 高27.205
- 今 开27.15
- 成交量 135.41万股
- 最 低 25.83
- 昨 收 26.76
- 总市值 32.80亿
- 52周最高 31.77
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 13.695
- 委 比 87.44%
- 总股本 1.25亿
- 历史最高 40.88
- 量 比 0.63
- 振 幅 5.14%
- 历史最低 1.76
- 每 手 1
- 风险率 4.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,731 common shares for $115,957.48
Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,731 common shares for $115,957.48 Arcutis Biotherapeutics director Howard G. Welgus cut his direct stake to 37,743 shares following option exercises and stock sales. Welgus exercised options for 4,096 shares at prices ranging from $6.52
06-18 08:40
Arcutis Stockholders Approve Proposals at 2026 Meeting
Arcutis Biotherapeutics ( ($ARQT) ) has shared an announcement. On June 5, 2026...
06-10 04:52
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 44,000 restricted stock units to six new employees under its 2022 Inducement Plan, vesting over four years. The awards were approved by the Compensation Committee to incentivize new hires, in compliance with Nasdaq Listing Rule 5635(c)(4). Arcutis, a medical dermatology company, focuses on innovative treatments for immune-mediated skin conditions.
06-05 20:00
Arcutis Biotherapeutics Published New Manuscript In American Journal Of Clinical Dermatology
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populationsThis is the second published manuscript from the Genital Psoriasis
06-03 20:07
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
The Genital Psoriasis Wellness Consortium, supported by Arcutis Biotherapeutics, has published a new manuscript in the *American Journal of Clinical Dermatology* offering expert-driven guidance for the diagnosis and management of genital psoriasis across pediatric, adult, and older populations. The paper emphasizes routine genital assessment, empathetic communication, and age-specific treatment approaches to address gaps in care for this under-re...
06-03 12:00
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8-10, 2026. A fireside chat is scheduled for June 9, 2026, at 2:00 p.m. ET. The webcast can be accessed via the Company’s website, with a replay available for 180 days p...
05-26 20:00
Arcutis Earnings Call Signals Momentum Amid Headwinds
Arcutis Biotherapeutics Inc (($ARQT)) has held its Q1 earnings call. Read on fo...
05-11 08:23
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics granted 40 new employees 269,000 restricted stock units and options for 70,000 shares under its 2022 Inducement Plan. The awards, approved by the Compensation Committee, vest over four years, with 25% vesting annually for restricted stock units and 25% on the first anniversary for options, followed by monthly vesting over three years. The stock options have a 10-year term and an exercise price of $23.35 per share, based on...
05-08 20:00
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $36 price target.
05-07 18:48
